Use of homoharringtonine in preparation of betacoronavirus replication inhibitor in human

Patent metadata

Field	Value
Publication number	US-2022016129-A1
Application number	US-202117407689-A
Country	US
Kind code	A1
Filing date	Aug 20, 2021
Priority date	Mar 30, 2020
Publication date	Jan 20, 2022
Grant date	—

Abstract

Disclosed is a use of homoharringtonine (HHT) in preparation of a drug against betacoronavirus infection, a use of homoharringtonine in preparation of a betacoronavirus replication inhibitor in human, and a formulation and a method for treating a disease caused by betacoronavirus. Through research, the HHT is found to not only have a good inhibitory effect on the first step of protein synthesis, but also have an unexpected inhibitory effect on each step of protein synthesis elongation, and can better inhibit the synthesis of long proteins. Because betacoronaviruses have longer ORFs and are more sensitive to the HHT, the HHT has a better replication inhibition effect on the betacoronaviruses, thus providing a feasible solution for controlling the replication of coronaviruses. The effects of the HHT on treating diseases caused by the betacoronaviruses including SARS-CoV-2 are confirmed for the first time by cell experiments and animal models.

First claim

1 . A drug against betacoronavirus infection, comprising a therapeutically effective amount of homoharringtonine.

2 . The drug according to claim 1 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

3 . The drug according to claim 1 , wherein the drug is in a dosage form of injection, oral formulation or inhalant.

4 . A betacoronavirus replication inhibitor, comprising a therapeuticallyeffective amount of homoharringtonine.

5 . The inhibitor according to claim 4 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

6 . The inhibitor according to claim 4 , wherein the inhibitor is in a dosage form of injection, oral formulation or inhalant.

7 . A formulation for treating a disease caused by a betacoronavirus, comprising at least one drug capable of improving the symptoms caused by betacoronavirus infection, and homoharringtonine, wherein the homoharringtonine is used for inhibiting replication of the betacoronavirus in vivo.

8 . The formulation according to claim 7 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

9 . The formulation according to claim 7 , wherein the formulation is in a dosage form of injection, oral formulation or inhalant.

10 . The formulation according to claim 7 , further comprising an acceptable pharmaceutical excipient.

11 . A method for treating a disease caused by betacoronavirus, comprising administering a therapeutically effective amount of homoharringtonine to a patient.

12 . The method according to claim 11 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

13 . The method according to claim 11 , further comprising administering at least one drug capable of improving the symptoms caused by betacoronavirus infection to patients.

14 . A method for treating a disease caused by betacoronavirus, comprising administering a therapeutically effective amount of the drug according to claim 1 .

15 . The method according to claim 14 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

16 . The method according to claim 14 , further comprising administering at least one drug capable of improving a symptom caused by betacoronavirus infection to the patient.

17 . A method for treating a disease caused by a betacoronavirus, comprising administering a therapeutically effective amount of the inhibitor according to claim 4 .

18 . The method according to claim 17 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

19 . The method according to claim 17 , further comprising administering at least one drug capable of improving a symptom caused by betacoronavirus infection to the patient.

20 . A method for treating a disease caused by a betacoronavirus, comprising administering a therapeutically effective amount of the formulation according to claim 7 .

21 . The method according to claim 20 , wherein the betacoronavirus is selected from HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2.

22 . The method according to claim 20 , further comprising administering at least one drug capable of improving a symptom caused by betacoronavirus infection to the patient.

Assignees

• Univ Sun Yat Sen

Inventors

• Wu Chungi
• Wen Haijun

Classifications

• A61K31/55 Primary

  having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title

• A61P31/14

  for RNA viruses · CPC title